Biotech Values

[iwfal]

Solanezumab binds soluble a-beta. According to the "sink hypothesis" removing peripheral, soluble a-beta should impact the insoluble a-beta deposits in brain plaques, in order to maintain equilibrium between the two forms.
Thanks, Idit. So, is it fair to say that the “sink hypothesis” has been discredited by the latest Solanezumab findings?

I'd suggest it would depend on:

a) The relative amount of insoluble a-beta vs soluble (I'd expect there to be a lot higher density of insoluble - so the sink would be disproportionate)

b) The rate constants that effect the conversion from insoluble to soluble. Given that it is plaque, I'd expect it to be 'sticky' - i.e a low rate constant.

I don't know either of the above parameters, but my question would be how confident are people that we do know those parameters?